\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage{float}

\begin{document}


\def\RunningAuthor{Arwa Mujahid Al-Shuwaikh et al.}
\firstPage{2234}
\articleType{Original Article}
\receivedDate{20 Feb 2020}
\acceptedDate{02 Apr 2020}
\revisedDate{26 Mar 2020}
\journalVolume{2020, 11}
\journalIssue{2}
\journalDoi{ijrps.v11i2.2181}
\copyrightYear{2020}
\def\authorCount{4}
\def\affCount{3}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{Molecular Detection of Epstein - Barr virus and Human Herpesvirus-6 in a Sample of Iraqi Patients with Acute Leukemia}
\author{Arwa~Mujahid~Al-Shuwaikh\textsuperscript{*}\textsuperscript{1},  
            Dalya~Basil~Hanna\textsuperscript{2},  
            Asmaa~B.~Al-Obaidi\textsuperscript{1}, 
            Ghaith~Ali~Jasim\textsuperscript{3}~\\[5pt]{\textsuperscript{1}Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq}~\\{\textsuperscript{2}Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq}~\\{\textsuperscript{3}Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq}}

\begin{abstract}
 The pathogenic roles of human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) in acute leukemia have been of great interest. Patients with leukemia should be evaluated for viral infection, so they could be diagnosed for optimal therapy. In the current study, we aimed to determine the frequency of HHV-6 and EBV in a sample of Iraqi patients with acute leukemia in children and adults before chemotherapy. Fluorescent probe-based quantitative polymerase chain reaction (Q-PCR) method was used to quantify copies of HHV-6 and EBV DNA in (ALL), 20 cases with acute myeloid lymphoblastic leukemia (AML), and 40 cases of hematological stable control subjects. Also, the effects of viral infection on hematological parameters were investigated. Results show that (47.5\%) 19 out of 40 of patients at diagnosis recorded positive to one of the investigated viruses. Thirteen (32.5\%) and 12 (30\%) out of 40 patients with acute leukemia had positive EBV and HHV-6 viremia, respectively, while none of control group shows positive result with highly significant differences between patients and control groups (P{\textless}0.001). The mean EBV and HHV-6 viral load was (7737.615\ensuremath{\pm}9106.838 copies/ml) and (94393.58\ensuremath{\pm}214528.9 copies/ml), respectively. In this study, there was no significant association between viral infection and hematological parameters (P{\textgreater}0.05). In conclusion, infections or co-infections with EBV and HHV-6 could be a factor in the development of acute leukemia but further studies are required to establish whether there is a real association.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Epstein-Barr virus,\newline Human Herpesvirus-6,\newline acute leukemia,\newline Q-PCR,\newline Iraq
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Arwa~Mujahid~Al-Shuwaikh~\\ Phone:\ +9647716799640~\\  Email:\ arwaalshwaikh2004@gmail.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Leukemia is a rapid progression of cancer in bone marrow and other blood forming tissues leading to abnormal blood cells to the blood stream. Different types of leukemia occur in adults and in children. The real causes of leukemia are not understood until now that leukemia is a multifactorial disease, some genetic and environmental factors are suspected to participate in developing of the leukemia \unskip~\citep{737643:17515735}.

Viruses such as, retrovirus and herpes virus families are etiological agents of human leukemia and lymphoma. Various epidemiological studies suggest that increased leukemia rate associated with developing of abnormal immune response against infectious agents especially during the childhood \unskip~\citep{737643:17515734}. Human herpesvirus-6 (HHV-6) is a member of herpesviridae family, with double strand DNA (160-162 kbp in size) and linear genome.

HHV-6 was first isolated from patients with lymph proliferative disorders \unskip~\citep{737643:17515718,737643:17515720}. HHV-6 integrates its DNA molecule in the cellular genes, this integration was reported in patients with acute lymphoblastic leukemia and noticed that this type of leukemia was transmitted from parents to their children which is found in about 1\% of the general population \unskip~\citep{737643:17515726,737643:17515723}. The presence of HHV-6 and the expression of the viral DR7B on coprotein have been reported in Reed-Sternberg cells from patients with Hodgkin's lymphoma patients.

DR7 reported to bind with tumor suppressor protein p53 and lead to inhibition of p53 activated transcription \unskip~\citep{737643:17515723}. HHV-6 latency is established in certain tissues, such as the salivary glands, T-cells and hematopoietic stem cells, and the virus can be reactivated in immune compromised hosts \unskip~\citep{737643:17515718,737643:17515720}. Epstein-Barr virus (EBV) is one of the most common viruses that belong to gamma-herpes virus; EBV has a linear genome with double-stranded DNA. The importance of EBV infection is the ability of the virus to become a latent virus after entering the body at any stage of life.

EBV infects 75\% of the population before age 5, and most people are infected with adulthood \unskip~\citep{737643:17515727,737643:17515729}. Regarding the viruses that have been proposed to play a role in the pathogenesis of acute leukemia, transforming viruses will integrate into the genome of precursor B cells, causing some disturbing in differentiation and proliferation stages of the cell.

The co-infection with EBV has suggested a probable linked with chronic lymphocytic leukemia in adults \unskip~\citep{737643:17515724,737643:17515728}. In addition to that many common pathogens may stimulate indirectly an unusual response especially in genetically and immunologically susceptible children, leading to autonomous precursor B-cell proliferation. When the viruses are integrated into the genome of precursor B cells this will directly promote leukemogenesis by acting on differentiation and proliferation \unskip~\citep{737643:17515734}. So far according to our knowledge, no study is available in Iraq regarding detection rate and viral load of EBV and HHV-6 in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in children and adults. The aim of this study was to detect the presence of EBV and HHV-6 in Iraqi patients with acute leukemia by quantitative real-time PCR. 
    
\section{Materials and Methods}
\textbf{Study population}

This study was approved by the Institutional Board Review committee (IBR) at Al-Nahrain College of Medicine, Baghdad, Iraq, written informed consent was obtained from each patient before conducting this study. Four (4) ml blood samples were obtained from 40 patients with acute leukemia (20 were ALL and 20 were AML) from Baghdad Center for Hematology in Medical City of Baghdad, Al Imamein Al Kadhimein Medical City and Central Teaching Hospital of Pediatrics in Baghdad. Specimens were taken from 20 children and 20 adults with acute leukemia before exposure to any therapy. All patients with leukemia were screened for hematological parameters: hemoglobin (Hb), packed cell volume (PCV), white blood cells (W.B.Cs), Neutrophil, lymphocyte.

In addition, blood samples were obtained from 40apparently healthy individuals from blood donating center in Al Imamein Al Kadhimein Medical City served as controls. The mean age of the patientswere16.85\ensuremath{\pm}13.37and 36.30 \ensuremath{\pm}23.31 years for ALL and AML patients, respectively (range, 2-68 years) and male to female ratio was 0.8:1. In this prospective study, all blood samples were obtained in sterile EDTA blood tubes, then at 1600 rpm for 20 min plasma separated by centrifugation, aliquot into two Eppendorf tubes and stored at (-40)\ensuremath{^\circ}C until used.

The diagnosis of leukemia in all patients was developed using clinical, morphological, laboratory investigations including peripheral blast cells of more than 30\%, bone marrow biopsy and fine needle aspiration cytology, and immunophenotypic criteria. Patients with secondary leukemia, hereditary hemolytic anemia and relapsing acute leukemia were excluded from this study.

\textbf{DNA Extraction}

Extraction of the viral DNA from plasma samples was done by DNA-sorb-B Extraction kit (Ref. K-1-1/B, Sacace Biotechnologies, Italy) according to instructions as follow: 10\ensuremath{\mu }l of internal control (IC)  was added to 300 \ensuremath{\mu }l of lysis solution then100\ensuremath{\mu }l of plasma was added, mixed andincubated at 65{\textdegree}C for 5 min and then centrifuged at 12000g for 5 sec; 25\ensuremath{\mu }l of sorbent was added to each tube and vortexed for 5 sec, incubated at room temperature for 10 min and vortexed periodically. Then centrifuged at 5000g for 1 min and the supernatant were discarded. 300\ensuremath{\mu }l of washing solution1was added vortexed vigorously, centrifuged at 5000g for 1 min and then the supernatant was discarded; 500 \ensuremath{\mu }l of washing solution2was added, vortexed vigorously, centrifuged at 10000g for 1 min, and then the supernatant was discarded. Washing step was repeated, and then the tubes were incubated with opened cap at 65\ensuremath{^\circ}C for 5 min. After that, 50\ensuremath{\mu }l of elution buffer were added and incubated at 65\ensuremath{^\circ}C for 5 minutes, vortexed periodically, centrifuged at 16000g for 2 min. Finally, the supernatant was collected, which contained purified genomic DNA, the purity of DNA extracts were measured using nanodrop (\ensuremath{\mu }LITEBioDrop, UK) and stored at -20\ensuremath{^\circ}C until further analysis by QPCR.

\textbf{Quantitative real time PCR}

Fluorescent probe-based real time PCR method was used for qualitative and quantitative detection of HHV-6 and EBV usingHHV6 Real-TM Quant (Ref.V10-100FRT, Sacace Biotechnologies, Italy) and EBV Real-TM Quant.

Real time PCR was performed with the Strata gene Mx3005P by use of primers and probe sequences that amplified a fragment of each virus including a specific region. For HHV-6 DNA copies detection, polymerase gene of HHV6 was targeted while for EBV DNA copies detection, latent membrane protein-1 (LMP) was targeted. During the sample preparation, internal control (IC) was added to serve as an amplification control for each individually processed specimen and to classify potential reaction inhibitions. The viral-gene DNA amplification was detected on JOE (Yellow)/HEX/Cy3 channel, while exogenous internal control was detected onRox(Orange)/Texas Red Channel included both positive and negative control to check the reaction validity.

The device was set according to the manufacturer's instructions. The master mix was prepared according to the manufacturer's instructions. For one reaction final volume of 25\ensuremath{\mu }L was prepared as following: 10\ensuremath{\mu }L of PCR-mix-1, 5\ensuremath{\mu }L of PCR-mix-2 buffer and 0.5\ensuremath{\mu }L of HotStart DNA polymerase, and then, 10\ensuremath{\mu }L of DNA from samples/standards positive or negative controls were added to the mix.

The real-time thermal condition included holding step for 1 cycle as initial activation of Hot Start DNA Polymerase at 95oC for 15min. Then two cycling steps: the first cycling step includes 5 cycles of denaturation at 95C for 5 sec, annealing at 60oCfor 20 sec, and extension at 72\ensuremath{^\circ}C for 15 sec, while the second cycling step includes40 cycles of denaturation at 95\ensuremath{^\circ}C for 5 sec, annealing at 60oCfor 30 sec, and extension at 72\ensuremath{^\circ}C for 15 sec with fluorescence data gathered during the second step (annealing step).

\textbf{Interpretation of results}

Real Time PCR instrument software interpreted the findings by crossing (or not crossing) the fluorescence curve with the threshold axis. The fluorescence is observed in JOE/Yellow/HEX/Cy3 and Red fluorescent channels ROX / Orange / Texas for EBV detection, although the fluorescence is observed in JOE/Yellow/HEX/Cy3 for HHV6 detection. For qualitative analysis, the samples were considered to be positive for DNA if the value of Ct is different from zero (Ct{\textless}35) in the channel JOE(Yellow)/HEX/Cy3, and they were interpreted as negative if the fluorescence signal is absent, the sensitivity of detection with EBV and HHV6 Real-TM Quantis approaching 200 and 100 copies/ml, respectively according to manufacturer. For each control and patient specimen, the concentration of EBV DNA copies/ml was calculated using the following formula,

$EBVDNA\;copies/ml=\frac{EBVDNA\;copies/reaction}{ICDNA\;copies/reaction}\times IC\;coefficient $

The concentration of HHV-6 DNA copies/ml was calculated using the following formula,

$HHV6\;DNA\;copies/ml=HHV6\;DNA/reaction\times100 $

\textbf{Statistical analysis}

Statistical package for social sciences (SPSS) version 23 was used for statistical analysis. Numerical data were presented as mean \ensuremath{\pm} standard deviation, and comparison between means of study groups was done by using independent student t-test or ANOVA. Categorical data were presented as frequency and percentage, and chi-square test was used for comparison between frequencies of study groups. P value less than 0.05 was considered as significant.
    
\section{Results}
The quantitative RT-PCR result shows EBV positivity in (32.5\%) 13 out of 40 in patients with acute leukemia where (30\%) 6 out of 20 in ALL group and (35\%) 7 out of 20 in AML groups, while all control group shows negative result, as shown in Table~\ref{tw-05fbac45bac2}. There was no significant differences between ALL and AML, however there were statistically significant differences between patients and control (p{\textless}0.05).


\begin{table*}[!htbp]
\caption{\boldmath {Comparison of EBV statusin different study groups} }
\label{tw-05fbac45bac2}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.1917\linewidth-2\tabcolsep}p{\dimexpr.2083\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\multicolumn{2}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{\cAlignHack EBV } & \multicolumn{2}{p{\dimexpr(.3917\linewidth-2\tabcolsep)}}{\cAlignHack Patients with acute leukemia} & Control Group\\
\rowcolor{kwdboxcolor}Infection &  & ALL Group & AML Group & \\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Negative}} &
  Count &
  14 &
  13 &
  40\\
 &
  Row N \% &
  70\% &
  65\% &
  100\%\\
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Positive}} &
  Count &
  6 &
  7 &
  0\\
 &
  Row N \% &
  30\% &
  35\% &
  0\%\\
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Total}} &
  Count &
  20 &
  20 &
  40\\
 &
  Row N \% &
  100\% &
  100\% &
  100\%\\
\multicolumn{2}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{P value between groups} &
  \multicolumn{3}{p{\dimexpr(.60\linewidth-2\tabcolsep)}}{0.0001}\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Comparison of HHV-6 status in different study groups} }
\label{tw-8fe29bf0e014}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20\linewidth-2\tabcolsep}p{\dimexpr.20549999999999997\linewidth-2\tabcolsep}p{\dimexpr.1945\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\multicolumn{2}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{\cAlignHack HHV-6 Infection} & \multicolumn{2}{p{\dimexpr(.4055\linewidth-2\tabcolsep)}}{\cAlignHack Patients with acute leukemia} & Control Group\\
\rowcolor{kwdboxcolor} &  & ALL Group & AML Group & \\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Negative}} &
  Count &
  14 &
  14 &
  40\\
 &
  Row N \% &
  70\% &
  70\% &
  100\%\\
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Positive}} &
  Count &
  6 &
  6 &
  0\\
 &
  Row N \% &
  30\% &
  30\% &
  0\%\\
\multicolumn{1}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{Total}} &
  Count &
  20 &
  20 &
  40\\
 &
  Row N \% &
  100\% &
  100\% &
  100\%\\
\multicolumn{2}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{P value between groups} &
  \multicolumn{3}{p{\dimexpr(.60\linewidth-2\tabcolsep)}}{0.001}\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Relationship betweenthe EBV, HHV-6 and the hematological parameters} }
\label{tw-021d44ae9440}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1519\linewidth-2\tabcolsep}p{\dimexpr.1281\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.16\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Parameter & \multicolumn{2}{p{\dimexpr(.26810000000000002\linewidth-2\tabcolsep)}}{\cAlignHack EBV-Status} &  P value & \multicolumn{2}{p{\dimexpr(.28\linewidth-2\tabcolsep)}}{\cAlignHack HHV-6 Status} &  P value\\
\rowcolor{kwdboxcolor}(Mean \ensuremath{\pm}SD) & Positive & Negative &  & Positive & Negative & \\
\tblmidrule 
 &
  21.26 \mbox{}\protect\newline \ensuremath{\pm}28.48 &
  25.92 \mbox{}\protect\newline \ensuremath{\pm}35.59 &
  0.682 &
  35.26 \mbox{}\protect\newline \ensuremath{\pm}33.41 &
  19.75 \mbox{}\protect\newline \ensuremath{\pm}32.52 &
  0.178\\
Neutrophils \% &
  29.42 \mbox{}\protect\newline \ensuremath{\pm}21.58 &
  21.89 \mbox{}\protect\newline \ensuremath{\pm}20.09 &
  0.285 &
  31.62 \mbox{}\protect\newline \ensuremath{\pm}22.91 &
  21.22 \mbox{}\protect\newline \ensuremath{\pm}19.15 &
  0.146\\
Lymphocyte \% &
  61.82 \mbox{}\protect\newline \ensuremath{\pm}22.13 &
  51.94 \mbox{}\protect\newline \ensuremath{\pm}27.13 &
  0.261 &
  57.15 \mbox{}\protect\newline   \ensuremath{\pm}24.84 &
  54.29 \mbox{}\protect\newline \ensuremath{\pm}26.54 &
  0.752\\
Hemoglobin (g/dl) &
  7.83 \mbox{}\protect\newline \ensuremath{\pm}2.16 &
  8.06 \mbox{}\protect\newline \ensuremath{\pm}2.24 &
  0.758 &
  8.08 \mbox{}\protect\newline \ensuremath{\pm}2.25 &
  7.94 \mbox{}\protect\newline \ensuremath{\pm}2.21 &
  0.859\\
PCV\% &
  24.84 \mbox{}\protect\newline \ensuremath{\pm}6.61 &
  24.00 \mbox{}\protect\newline \ensuremath{\pm}6.49 &
  0.706 &
  24.733 \mbox{}\protect\newline \ensuremath{\pm}6.56 &
  24.08 \mbox{}\protect\newline \ensuremath{\pm}6.52 &
  0.776\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/f3b02e6a-2d20-4f24-b064-c0f778e9ecc4-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/f3b02e6a-2d20-4f24-b064-c0f778e9ecc4-upicture1.png}{\includegraphics{images/f3b02e6a-2d20-4f24-b064-c0f778e9ecc4-upicture1.png}}{}
\makeatother 
\caption{\boldmath {Comparison of mean HHV-6 and EBV viral load in different study groups}}
\label{f-8b14c6203f75}
\end{figure}
\egroup
The result shows HHV-6 positive viremia in (30\%) 12 out of 40 in patients with acute leukemia where (30\%) 6 out of 20 in each of ALL and AML groups, while none of control group shows positive result with statistically significant differences between patients and control (P{\textless}0.05), as shown in Table~\ref{tw-8fe29bf0e014}. In addition, (15\%) 6 out of 40 of patients shows co-infection with both EBV and HHV-6. Interestingly, (47.5\%) 19 out of 40 of patients positive to one of the investigated viruses either EBV \&/or HHV-6 (data not shown).

Quantitative real time PCR (QRT-PCR) run gave positive EBV viremia in (32.5\%) of patients, the mean copy number was (8895.714\ensuremath{\pm}12235.12; range: 422-10677) copies/ml in AML patients and (6386.5\ensuremath{\pm}3916.2; range: 600-35550) copies/ml in ALL patients. For HHV-6, the viremia was detected in (30\%) of patients, the mean copy number was (167701.2\ensuremath{\pm}296600; range: 420-770090) copies/ml in AML patients and (21086\ensuremath{\pm}19511.58; range: 266-40890) copies/ml in ALL patients. However, the mean EBV and HHV-6 viral load was (7737.615\ensuremath{\pm}9106.838 vs. 94393.58\ensuremath{\pm}214528.9) copies/ml, respectively, as shown in Figure~\ref{f-8b14c6203f75}.

Patients with acute leukemia were categorized into two groups according to the viral status. Then data were analyzed with student t-test, result shows that there was no significant difference according to hematological parameters between the EBV positive and EBV negative patients, neither between the HHV-6 positive and HHV-6 negative patients as shown in Table~\ref{tw-021d44ae9440}.
    
\section{Discussion}
Various theories have indicated an infectious etiology of cancer, supporting either direct or indirect transformation mechanisms. Related pathways include viral oncogene expression along with cellular tumor suppressor gene deregulation, indirect mechanisms are mainly elicited by inflammation, mutagenic molecules production or immune suppression with lack of immune surveillance against cancer \unskip~\citep{737643:17515731}.

Smith suggests that oncogenic viruses can infect immature lymphocytes during the first year of life and encourage leukemia through a process that is direct \unskip~\citep{737643:17515717}. In the present study we selected members of the herpesviridae family, EBV and HHV6 because they are lymph tropic viruses often transmitted in the first months of life. We found that (47.5\%) 19 out of 40 of patients were positive by at least one of the viruses tested. Results revealed that 13 out of 40 (32.5\%) of patients were positive for EBV-DNA, distributed as 6 out of 20 (30\%) of ALL and 7 out of 20 (35\%) of AML, on the other hand, all healthy control was negative Table~\ref{tw-05fbac45bac2}.

This result is comparable to that reported by \unskip~\cite{737643:17515729} who found that the distribution of EBV LMP1 in pediatric leukemia patients is(42.6\%),(33.3\%)and (0\%) in ALL, AML and control, respectively using conventional PCR  technique (Ahmed et al., 2012). Several studies have noted that EBV may contribute to the pathogenesis of acute leukemia \unskip~\citep{737643:17515728,737643:17515729,737643:17515735}. Other studies find no proof of EBV's involvement in ALL development \unskip~\citep{737643:17515730,737643:17515731}.

EpsteinBarr infects about 90 percent of adults and about 50 percent of children around the world \unskip~\citep{737643:17515735,737643:17515722}. Exposure to oral secretions during kissing has been identified as the major source for primary EBV infection in adolescents and younger children \unskip~\citep{737643:17515722}. However, primary infections by EBV have been reported in a small number of children with ALL in remission and the course of the infection did not appear to be influenced by either the underlying leukemia or chemotherapy \unskip~\citep{737643:17515715}. Since infectious mononucleosis (IM) has been documented as a preceding event in some cases of ALL as well as other lymphocytic neoplasms, it is possible that EBV may be able to activate or ``switch-on'' an oncogenic process in a manner similar to that described for murine leukemia \unskip~\citep{737643:17515721}. In the present study, utilizing sensitive and specific technique like QPCR, this result found that (32.5\%) of our patients had infected with EBV and the percentage might be higher than this due to the fact that we only detected LMP1 gene, which could detect the majority of cases but not all cases, that may bear a causal relationship. However, positive samples showed low viral load (8895.714\ensuremath{\pm}12235.12; range: 422-10677), Figure~\ref{f-8b14c6203f75}.

Such findings do not support an EBV's direct function in the development of Iraqi patients with acute leukemia. It is stated that lymphocyte chromosome mutations or translocation induced by an EBV infection can result in c-myc Oncogene activation and excessive expression, leading to lymphoma eventually \unskip~\citep{737643:17515733}. Although there is no theoretical link between EBV and the pathogenesis of AML \unskip~\citep{737643:17515728,737643:17515729,737643:17515735}, however, EBV diagnostic tests is recommended in pediatric patients with AML \unskip~\citep{737643:17515732}. The current study, HHV-6 was detected in 12 out of 40 (30\%) of acute leukemia patients (viral load 94393.58 \ensuremath{\pm} 214528.9 copies/ml), distributed as 6 out of 20 (30\%) in each of ALL and AML patients, Table~\ref{tw-8fe29bf0e014} and Figure~\ref{f-8b14c6203f75}. This is comparable to other studies \unskip~\citep{737643:17515716}. \unskip~\cite{737643:17515719} reported that a total of 24.7\% of ALL children were positive for HHV-6 genome. \unskip~\cite{737643:17515716}  reported higher HHV-6 detection rate (36\%) with a higher viral load in blood. In contrast, a study showed that HHV-6 was found in only 15\% of patients with acute leukemia at diagnosis \unskip~\citep{737643:17515723}. However, a study on pediatric ALL failed to reveal a causal relationship of the virus with ALL \unskip~\citep{737643:17515731}. The differences in the frequency of HHV6 may be due to variability in patient cohorts, and to different qPCR sensitivities. \unskip~\cite{737643:17515723}  found that HHV-6 was significantly more prevalent in blood and bone marrow at remission than at diagnosis which indicated viral reactivation after chemotherapy rather than a causal role of HHV-6 in the genesis of acute leukemia \unskip~\cite{737643:17515723}. However, the presence of HHV-6 is interpreted either as a secondary event of immune suppression, as an incidental finding, or as a causal for the disease \unskip~\citep{737643:17515720}. The current study showed that there was no significant difference according to hematological parameters and viral positivity at diagnosis of leukemia, Table~\ref{tw-021d44ae9440}, \unskip~\cite{737643:17515735} reported that among ALLs, WBC counts were higher in the EBV positive group than in the EBV negative group; this was caused by EBV infection that led to high WBC counts.
    
\section{Conclusions}
Our result could be explained by differences in samples size, viral load and stage of disease. There are many studies from Iraq on leukemia but to the best of our knowledge no previous study screened patients for EBV and HHV-6 before the induction of chemotherapy. In conclusion, this study detected EBV and HHV-6 nucleic acid in patients with leukemia, which is interesting finding in our community. Thus, in order to investigate the possible role of viral infection in acute leukemia, more molecular techniques with greater sample sizes are needed.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
